What it is exactly in this phase 1 trial in health volunteers...

First 11 Last

Share
Profile

Follow
Duke2

775 Posts.

196

26/02/24

20:49

Post #: 72606464
Share

Originally posted by MajorJohnny: ↑

Not long to go now until the Final piece of data for the Phase 1 study to be released. Investors need to remember it has taken several years to get to where they are now and around $45 million. Multiple partnering opportunities to move ahead in the near term depending on the quality of release of data and how well they sell it .

Several Licensing partners seem to be eagerly awaiting the release of the final data. Also bullish to see Financial Investors interested in taking on risk with the funding of Phase 11 in return for a share of the asset which would reduce the need for further major dilution to current investors. The fact that the Market Cap is still trading in a $10 to $12 million range with high impact news to come makes this option even more appealing for Adalta limited.

This could be a reason the stock price is being held down so that interested Financial Investors can negotiate a better deal upon the release of final data. It is a different world when investing in this neck of the woods and if you think it is a level playing field you are living in the twilight zone.

Expand

What it is exactly in this phase 1 trial in health volunteers that you are expecting to be "high impact"? I think investors remember loud and clear that it has taken years and 45 million dollars to get to this place and that's the very reason not many people want to invest here.

As far as I can see the company has just stuffed around since 2021 when they initially shelved the IV route to pivot to inhaled, and then shelved that and pivoted back to IV.

I fail to see how any deals will be struck on phase 1 results, when essentially the same results were known in 2021 and will just be replicated at a higher dose...

1AD Price at posting: 2.2¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply